Soligenix Says Unable To Provide Pre-Requisite Amount Of Accrued Stability Data Required To File Its Hybryte NDA With FDA By First Half Of 2022; Says Timeline For Anticipated NDA Filing With FDA Is Being Adjusted To H2 2022